Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis

Nico Gagelmann(Universität Hamburg), Nicolaus Kröger(Universität Hamburg), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Francis Ayuk(Universität Hamburg), Marcelo C. Pasquini(Cleveland Clinic), Michael R. Bishop(University of Chicago), Bertram Glaß(Helios Hospital Berlin-Buch), Wolfgang Bethge(University of Tübingen)
Transplantation and Cellular Therapy
January 26, 2024
10.1016/j.jtct.2024.01.074
Cited by 45

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795